MIT in Medical Technology

Stand Up To Cancer Awards $73.6 Million for Novel, Groundbreaking Cancer Research

...the Massachusetts Institute of Technology and David H. Koch Institute at mit . Sharp chairs the Scientific Advisory Committee (SAC) assembled by SU2C's ...the Massachusetts Institute of Technology and David H. Koch Institute at mit , Chair of SU2C Scientific Advisory Committee Raymond N. DuBois, M...

Why Wait for an Anti-Aging Drug? Researchers Interviewed on CBS-TV's 60 MINUTES Discover Longevinex(R) Nutriceutical Matrix Activates 9-Fold More Longevity Genes than Plain Resveratrol

...t cells, fruit flies and round worms to live longer. SIR2 is a gene that is similar to Sirtuin1 in humans. But only recently have researchers at mit come to realize the Sirtuin1 gene is not activated in all tissues and organs in calorie restricted animals, so it may not serve as a universal marker...

Seahorse Bioscience Announces the XF96 Extracellular Flux Analyzer for Cellular Bioenergetics

...vant assay for detecting the effect of RNAi knockdown of mitochondrial genes on cellular bioenergetics," added Vamsi Mootha, from the Broad Institute, mit and Harvard's Massachusetts General Hospital. "This technology may accelerate the discovery of drugs for mitochondrial diseases." The XF96 extracell...

Pharmaleads' Lead Candidate for Pain, PL37, Enters Phase I

..., alumnus from Polytechnique and Mines, PhD from Stanford, (former Deputy General Manager, Suez Group) and Jean-Pierre Rogala, PhD from Agro, MBA from mit (IBM, Suez Group). They were able to bring in their first rank international business expertise to fully unleash the world-class capabilities of the c...

Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies

...prostate lung, breast and colon cancer. PAN-622 and other antibodies covered under U.S. Patent Number 7,413,737 were developed in collaboration with mit using a proprietary yeast display technology. More detailed information is included in Yeung YA, Finney AH, Koyrakh IA, Lebowitz MS, Chanbari HA, Wand...

Four Alzheimer's Clinical Trials Address a Variety of Treatment Targets - Amyloid, Tau, Synapse Formation

...d(TM)." "Souvenaid(TM) is a medical food product backed by 10 years of research. Much of the conceptual work and early pre-clinical work was done at mit under Professor Richard Wurtman, and supported principally by the National Institutes of Health," Scheltens added. About ICAD 2008 The 2008 Alzhei...

Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-093 in Patients with Rheumatoid Arthritis

... any international regulatory agency. The company's proprietary Network Biology discovery platform, developed with the help of leading scientists from mit and Harvard, enables the high throughput profiling of protein networks as a basis for improved validation, lead identification and speed in the develo...

VIVUS Announces Abstract Published at American Diabetes Association Scientific Sessions

...co-morbidities were also reduced. About Dr. Najarian Thomas Najarian, M.D., a Board Certified Specialist in Internal Medicine, is a graduate of mit (SB, SM in Mechanical Engineering) and Harvard Medical School. He is a former faculty member of the Harvard Medical School. Dr. Najarian was the forme...